GEREF
LOE Approachingsermorelin acetate
NDAINJECTIONINJECTABLE
Approved
Sep 1997
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 6d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GEREF (sermorelin acetate) is a synthetic growth hormone-releasing hormone (GHRH) analog administered by injection. It stimulates the anterior pituitary gland to release endogenous growth hormone, used primarily for growth hormone deficiency in children and adults. The drug works by mimicking the body's natural GHRH signaling pathway to restore physiologic GH secretion.
LOE Approaching
Approaching loss of exclusivity with moderate competitive pressure signals shrinking team size and transition focus toward generic defense or portfolio repositioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GEREF positions offer limited current hiring activity, reflecting its LOE-approaching lifecycle stage. Roles available are primarily focused on maintaining market share and managing the transition through patent expiry rather than driving expansion.
Brand ManagerMedical Science Liaison
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.